Tyra Biosciences Inc [TYRA] stock is trading at $10.26, up 6.32%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The TYRA shares have gain 14.13% over the last week, with a monthly amount drifted -2.29%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, UBS started tracking the stock with Buy rating on January 07, 2025, and set its price target to $28. On October 18, 2024, upgrade upgraded it’s rating to Buy and revised its price target to $31 on the stock. Piper Sandler started tracking the stock assigning a Overweight rating and suggested a price target of $33 on August 15, 2024. BofA Securities downgraded its rating to a Neutral and reduced its price target to $15 on December 15, 2023. Wedbush started tracking with a Outperform rating for this stock on June 30, 2023, and assigned it a price target of $27. In a note dated February 03, 2023, Oppenheimer initiated an Outperform rating and provided a target price of $17 on this stock.
Tyra Biosciences Inc [TYRA] stock has fluctuated between $6.42 and $29.60 over the past year. Currently, Wall Street analysts expect the stock to reach $31.75 within the next 12 months. Tyra Biosciences Inc [NASDAQ: TYRA] shares were valued at $10.26 at the most recent close of the market. An investor can expect a potential return of 209.45% based on the average TYRA price forecast.
Analyzing the TYRA fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.28, Equity is -0.27 and Total Capital is -0.35. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Tyra Biosciences Inc’s Current Ratio is 22.78. Further, the Quick Ratio stands at 22.78, while the Cash Ratio is 7.07.
Transactions by insiders
Recent insider trading involved Kjellson Nina S, Director, that happened on Feb 05 ’25 when 5401.0 shares were sold. Director, Canaan XI, LP completed a deal on Feb 05 ’25 to buy 0.12 million shares. Meanwhile, Director Canaan 2020 Plus Co-Investment bought 0.11 million shares on Feb 05 ’25.
